For Bayer, a Supreme Court Win Isn't the Same as a Clean Balance Sheet

Bayer stock up 27% after Supreme Court win, but €33B debt and negative free cash flow test rally ahead of Q2 results.

Bayer’s stock has surged more than 27% over the past 30 days, riding a wave of optimism after the US Supreme Court handed the company a decisive legal victory in late June. But behind the rally lies a financial picture that gives even the most bullish analysts reason to pause: net debt is forecast to climb toward €33 billion, and free cash flow is expected to remain deeply negative this year.

The high court’s 7–2 ruling in Monsanto v. Durnell effectively blocks state-level lawsuits over missing cancer warnings on glyphosate products, as long as the Environmental Protection Agency has approved the labeling. Bayer moved swiftly to capitalize on the decision, filing a motion on July 12 in a San Francisco federal court to dismiss a consolidated case involving roughly 4,000 individual claims. If granted, the motion would remove a significant chunk of the remaining Roundup litigation.

That legal momentum has not, however, erased the strain on Bayer’s balance sheet. The company expects to pay out around €5 billion in litigation-related costs this year, driving free cash flow to between minus €2.5 billion and minus €1.5 billion. Net financial debt, which had improved to roughly €29.8 billion at the end of 2025, is now projected to land between €32 billion and €33 billion by year-end. A rating agency has already flagged that recent capital measures have not fully resolved the structural concerns in the books.

Analyst opinion reflects the split between legal relief and financial discipline. JPMorgan’s Richard Vosser kept an “Overweight” rating with a €50 target on July 17, citing the fundamental easing of legal risk. Jefferies’ Michael Leuchten was more cautious, maintaining a “Hold” and a €46 target on July 13, arguing that Bayer needs to strengthen its balance sheet before pursuing further structural moves. The stock closed last Friday at €48.06, roughly 11% below its 52-week high of €53.86 reached on July 3.

While the legal front offers a tailwind, Bayer is also trying to build a new growth engine. On July 15, the company signed an exclusive licensing deal with French seed breeder RAGT to jointly develop hybrid wheat for Europe and North America. The product is not expected to launch until the early 2030s, but Bayer sees annual sales potential of up to €1 billion by the mid-2040s. It is a long-term bet that underscores the firm’s commitment to its agriculture division even as it wrestles with legacy liabilities.

The next few weeks will test whether the stock can hold its gains. Bayer publishes its second-quarter results on August 4, giving investors a chance to gauge whether cash flow trends are beginning to improve. Just two weeks later, on August 19, a fairness hearing in Missouri will examine a proposed nationwide settlement for Roundup claims. A successful outcome there would remove one of the biggest overhangs on the stock. On September 2, the company will also host an investor event for its Crop Science division.

With an annualized volatility of 62%, Bayer’s shares are no strangers to sharp swings. The market has already priced in a legal resolution, but it has yet to fully trust the operational turnaround. If the August numbers disappoint or the settlement hearing hits a snag, the debt burden of €32–33 billion could quickly become the dominant narrative again.